The correlation between PSA and benign prostate hyperplasia, prostate inflammation, and PCa makes it a marker with broad clinical utility; however, it is a complex tool in terms of confirming the cancer diagnosis, with a 60%–70% false positive rate (1–3). This evidence concerns the gene KLK3 and benign prostatic hyperplasia.